| Nov 12 |
Vincerx Pharma GAAP EPS of -$0.17
|
| Nov 12 |
Vincerx Pharma Reports Third Quarter 2024 Financial Results
|
| Oct 10 |
What Makes Vincerx Pharma (VINC) a New Buy Stock
|
| Oct 8 |
Vincerx stock tumbles 20% on corporate updates
|
| Oct 7 |
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
|
| Aug 21 |
Companies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite Risky
|
| Aug 9 |
Vincerx Pharma GAAP EPS of -$0.05
|
| Aug 8 |
Vincerx Pharma Reports Second Quarter 2024 Financial Results
|
| Jun 27 |
Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
|
